Go to
JCI Insight
About
Editors
Consulting Editors
For authors
Publication ethics
Publication alerts by email
Advertising
Job board
Contact
Clinical Research and Public Health
Current issue
Past issues
By specialty
COVID-19
Cardiology
Gastroenterology
Immunology
Metabolism
Nephrology
Neuroscience
Oncology
Pulmonology
Vascular biology
All ...
Videos
Conversations with Giants in Medicine
Video Abstracts
Reviews
Reviews
View all reviews ...
Review Series
Complement Biology and Therapeutics (May 2025)
Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
Microbiome in Health and Disease (Feb 2025)
Substance Use Disorders (Oct 2024)
Clonal Hematopoiesis (Oct 2024)
Sex Differences in Medicine (Sep 2024)
Vascular Malformations (Apr 2024)
View all review series ...
Viewpoint
Collections
In-Press Preview
Clinical Research and Public Health
Research Letters
Letters to the Editor
Editorials
Commentaries
Editor's notes
Reviews
Viewpoints
100th anniversary
Top read articles
What should define a SARS-CoV-2 “breakthrough” infection?
John S. Schieffelin, … , Elizabeth B. Norton, Jay K. Kolls
John S. Schieffelin, … , Elizabeth B. Norton, Jay K. Kolls
Published May 11, 2021
Citation Information:
J Clin Invest.
2021;
131(12)
:e151186.
https://doi.org/10.1172/JCI151186
.
View:
Text
|
PDF
Viewpoint
What should define a SARS-CoV-2 “breakthrough” infection?
Text
PDF
Abstract
Authors
John S. Schieffelin, Elizabeth B. Norton, Jay K. Kolls
×
Full Text PDF
Download PDF
(303.25 KB)
